IP Library Granted Patent US 10,150,999
Granted Patent B2
US 10,150,999 · App. 13/299,226 · Granted Dec 11, 2018

miRNAs as biomarkers for distinguishing benign from malignant thyroid neoplasms

Inventors: Sylvie Beaudenon-Huibregtse (Austin, TX); Ashish Choudhary (Austin, TX)
Assignee: INTERPACE DIAGNOSTICS, LLC
C12Q1/6886C12Q2600/112C12Q2600/158C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,150,999
App. No.
13/299,226
Granted
Dec 11, 2018
Kind
B2
Abstract

The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as thyroid nodules or thyroid cancer, and using the profile in the diagnosis of a patient for a condition, such as thyroid nodules or thyroid cancer.

Claims (11)

1. A method of treating a subject identified with a papillary thyroid carcinoma, the method comprising:

producing labeled nucleotide sequences from a thyroid sample from a subject;

contacting the thyroid sample from the subject with labeled primers specific for a group of microRNAs consisting of miR-375, miR-146b-5p, mir-138-1*, and miR-204; and

reacting the sample with the labeled primers under conditions to amplify the microRNAs using polymerase chain reaction to produce the labeled nucleotide sequences;

measuring expression levels of microRNAs miR-375, miR-146b-5p, mir-138-1*, and miR-204 from the unclassified thyroid sample from the subject with the labeled modified nucleotide microRNA probes that bind specifically to miR-375, miR-146b-5p, mir-138-1*, and miR-204 to produce a microRNA profile based upon the binding of the labeled nucleotide microRNA probes and the labeled nucleotide sequences produced using the polymerase chain reaction;

comparing the expression levels of the microRNAs in the profile from the unclassified thyroid sample from the subject to a normal thyroid reference level for each miRNA;

identifying the unclassified thyroid sample as papillary thyroid carcinoma when the profile expression levels of miR-375, miR-146b-5p are increased as compared to the normal reference level and mir-138-1* and miR-204 are decreased as compared to the normal reference level; and

treating the subject whose sample was identified as papillary thyroid carcinoma, wherein the treating comprises administering radioactive iodine, radiation, or chemotherapy to the subject identified as having papillary thyroid carcinoma or performing a thyroidectomy on the subject identified as having papillary thyroid carcinoma.

2. The method of claim 1 , wherein the sample is a biopsy.

3. The method of claim 2 , wherein the biopsy is surgical resection or a fine needle aspirate.

4. The method of claim 1 , further comprising obtaining a sample from the subject.

Assignments (14)
SECURITY INTEREST Recorded Nov 2, 2021
From: INTERPACE BIOSCIENCES, INC.; INTERPACE DIAGNOSTICS CORPORATION; INTERPACE DIAGNOSTICS, LLC; INTERPACE PHARMA SOLUTIONS, INC.
To: BROADOAK FUND V, L.P.
Reel/Frame 057988/0110 →
SECURITY INTEREST Recorded Oct 20, 2021
From: INTERPACE DIAGNOSTICS, LLC
To: COMERICA BANK
Reel/Frame 057851/0305 →
RELEASE OF SECURITY INTEREST Recorded Jun 16, 2017
From: HUDSON BAY MASTER FUND LTD
To: INTERPACE DIAGNOSTICS CORPORATION
Reel/Frame 042856/0895 →
RELEASE OF SECURITY INTEREST Recorded Jun 16, 2017
From: HUDSON BAY MASTER FUND LTD
To: INTERPACE DIAGNOSTICS GROUP, INC.; INTERPACE BIOPHARMA, LLC; INTERPACE DIAGNOSTICS, LLC; INTERPACE DIAGNOSTICS LAB, INC.; INTERPACE DIAGNOSTICS CORPORATION
Reel/Frame 042840/0860 →
RELEASE OF SECURITY INTEREST Recorded Jun 16, 2017
From: HUDSON BAY MASTER FUND LTD
To: INTERPACE DIAGNOSTICS GROUP, INC.; INTERPACE DIAGNOSTICS, LLC; INTERPACE DIAGNOSTICS CORPORATION
Reel/Frame 042856/0799 →
RELEASE OF SECURITY INTEREST Recorded Jun 16, 2017
From: HUDSON BAY MASTER FUND LTD
To: INTERPACE DIAGNOSTICS CORPORATION
Reel/Frame 042858/0971 →
SECURITY INTEREST Recorded Mar 27, 2017
From: INTERPACE DIAGNOSTICS GROUP, INC.
To: HUDSON BAY MASTER FUND LTD
Reel/Frame 041754/0517 →
JOINDER TO GUARANTEE AND COLLATERAL ASSIGNMENT Recorded Sep 23, 2016
From: INTERPACE DIAGNOSTICS CORPORATION; PDI, INC.; GROUP DCA, LLC; INTERPACE BIOPHARMA, LLC; INTERPACE DIAGNOSTICS, LLC; JS GENETICS, INC.
To: REDPATH EQUITYHOLDER REPRESENTATIVE, LLC
Reel/Frame 040127/0018 →
GUARANTEE AND COLLATERAL AGREEMENT Recorded Sep 23, 2016
From: PDI, INC.; GROUP DCA, LLC; INTERPACE BIOPHARMA, LLC; INTERPACE DIAGNOSTICS, LLC; JS GENETICS, INC.; REDPATH ACQUISITION SUB, INC.
To: REDPATH EQUITYHOLDER REPRESENTATIVE, LLC
Reel/Frame 040125/0251 →
RELEASE OF SECURITY INTEREST Recorded Feb 22, 2016
From: SWK FUNDING LLC
To: INTERPACE DIAGNOSTICS LLC
Reel/Frame 037784/0629 →
SECURITY INTEREST Recorded Nov 10, 2014
From: INTERSPACE DIAGNOSTICS, LLC; JS GENETICS, INC.; GROUP DCA, LLC; PDI, INC.
To: REDPATH EQUITYHOLDER REPRESENTATIVE, LLC
Reel/Frame 034136/0060 →
SECURITY INTEREST Recorded Nov 4, 2014
From: INTERPACE DIAGNOSTICS, LLC
To: SWK FUNDING LLC, AS AGENT
Reel/Frame 034103/0278 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2014
From: ASURAGEN, INC.
To: INTERPACE DIAGNOSTICS, LLC
Reel/Frame 033605/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2012
From: BEAUDENON-HUIBREGTSE, SYLVIE; CHOUDHARY, ASHISH
To: ASURAGEN, INC.
Reel/Frame 027572/0401 →
Continuity (2)
Provisional Application 61414778 · Nov 17, 2010
Related Publication 20120157334A1 · Jun 21, 2012